Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose every-other-day relugolix study in endometriosis or uterine fibroids
jRCTs031220707Suspended
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of tissue-plasminogen activator in endometriosis and Fibromyoma (LM). Primary endpoint: Change in menopausal symptoms. Started Mar 2023; status: suspended.
02
Drugs
tissue-plasminogen activator
03
Conditions
endometriosisFibromyoma (LM)
Beyond the preview
Go deeper on jRCTs031220707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220707.